公司资料
Shattuck Labs 股价、新闻与催化剂
- 股票代码:
- STTK
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.39 USD (-0.40%)
收盘价
最后更新: 2026年8月17日
373M USD
市值
股价为何变动
As of Aug 17, 2026, STTK closed down 0.40% at $7.39. No new same-company headline was identified in the current news window.
公司概览
Immune-Mediated Diseases
Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells.
SL-325
SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and multiple-ascending-dose study and is being prepared for Phase 2 development in Crohn's disease.
DR3 Platform
Shattuck is also exploring bispecific DR3-blocking antibodies and additional indications where excessive DR3 signaling may contribute to chronic inflammation.
未来催化剂
- Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
- Initiation of a Phase 2 study of SL-325 in Crohn's disease in the third quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。